Best Healthcare Stocks this May 2026 in the UK

AstraZeneca, a leading pharmaceutical firm with a diverse therapeutic focus, is currently trading at £139.56 and boasts a market cap of £217.9bn. Despite a recent analyst downgrade and concerns surrounding its operations in China, the company remains an interesting option for long-term investors, holding a B+ rating and a strong pipeline of products.

AstraZeneca's stock has dropped due to recent analyst downgrades and concerns about its China subsidiary, despite a strong pipeline and strategic acquisitions.

AstraZeneca is rated #3 (Hold) by Zacks, with a VGM Score of B, and has shown positive momentum with a 5.5% increase in shares over the past month.

The consensus rating for AstraZeneca is 'Buy', with 20 out of 21 analysts recommending to buy the stock.

Hikma Pharmaceuticals, currently priced at UK£13.85 and boasting a low PE ratio of 10.1x, offers strong value metrics that may appeal to investors. With a dividend yield of nearly 5%, it provides an attractive option for those seeking reliable income despite facing some risks, including competitive pricing pressures in the U.S. Analysts have rated the stock an A-, predicting a potential upside of approximately 36.39% based on their average price targets.

Analysts have a median price target of 1,830.36 for Hikma Pharmaceuticals, suggesting a potential 32.73% increase from its current price of 1,379.00.

Key risks include intense price competition in the US market and potential product quality or safety issues.

Hikma Pharmaceuticals has a potential upside of 36.39% based on analysts' average price target.

Hikma's shares have declined due to increased competition affecting injectables margins, and its new manufacturing facility in Ohio will not be operational for another two years.

Spire Healthcare Group, the UK's largest independent network of private hospitals, currently presents an investment opportunity with a dividend yield of 0.93%. Despite facing a 14.09% decline over the past year and a 16.99% drop in the last five years, analysts have rated the stock a B+, highlighting its potential for recovery amid ongoing market challenges.

Spire Global (SPIR) reported a 44% year-over-year revenue growth in Q4 2025, reaching $15.8 million, and improved its non-GAAP gross margin to 43% from 38% the previous year.

The median target price for Spire Healthcare Group PLC is 277.50, with estimates ranging from a low of 179.00 to a high of 300.00.

Smith & Nephew, a highly regarded UK healthcare provider, is featured among the best stocks for 2026, emphasizing its commitment to delivering consistent returns. With a current dividend yield of 2.43% and a one-year return of 17.80%, it stands out as a solid choice for investors seeking reliable income from financially healthy companies. Analysts have set a price target of $32.00, reflecting a B+ rating, with forecasts indicating strong growth in earnings and revenue over the coming years.

SNN has a Zacks Rank of #2 (Buy) and a Forward P/E ratio of 16.77, which is lower than the industry average of 19.62.

SNN is projected to grow earnings by 12.9% and revenue by 5.5% annually, with an expected EPS growth of 13.6%.

SNN has a GF Score of 87/100, indicating strong financial performance, but it is currently overvalued by about 5.5% compared to its intrinsic value.

Lakeland Industries has a consensus rating of Buy from analysts, with 67% recommending a Strong Buy.

Advanced Medical Solutions Group (AMS) is currently trading at £2.53, reflecting a significant 10.7% increase over the past week. With a strong analyst consensus rating of "Strong Buy," 80% of analysts advocate for purchasing this UK medical device company, highlighting its reliability and potential for consistent returns. Investors can benefit from a modest dividend yield of 1.14% and a remarkable one-year return of 36.68%, making AMS an attractive option for those seeking growth in a financially healthy sector.

50% of analysts recommend a Strong Buy, 40% recommend Buy, and 10% suggest Holding, indicating a generally positive outlook.

The consensus rating for Advanced Medical Solutions is a Strong Buy, with all 8 analysts recommending to buy the stock.

80% of analysts recommend buying AMS, indicating a mildly positive sentiment.

Analysts have a median price target of 275.00 for Advanced Medical Solutions, representing an 8.48% increase from its last price of 253.50.

Inspiration Healthcare Group (IHC) stands out as a top-rated UK healthcare company, having achieved an impressive 1-year return of 70.35%. With a dividend yield of 1.56%, it presents an attractive option for investors looking for consistent income amidst strong market performance. However, over the past five years, the stock has seen a significant decline of 75.10%, which potential investors should consider carefully.

Analysts recommend 25% Strong Buy, 38% Buy, and 38% Hold for Crown Castle, with no recommendations for Sell or Strong Sell.

HeartBeam (BEAT) has a consensus rating of Strong Buy, with 100% of analysts recommending this rating.

ICL (ICL) has an AI Score of 3/10, indicating a Sell recommendation, with a -3.48% probability of outperforming the S&P 500 in the next three months.

Craneware (CRW), a prominent player in the UK healthcare software sector, presents an appealing investment opportunity with a dividend yield of 1.84%. However, it's worth noting that it has seen a decline of 3.20% over the past year and a 15.83% drop over the last five years, which could raise concerns for potential investors. Analysts rate Craneware as a B, indicating a solid outlook amidst its current challenges.

The current price of Toys R Us (TOYRF) is $0.0040, reflecting a decrease of 86.67% in the past 24 hours.

Thermal Energy International Inc. (TMG) has a consensus rating of 'Strong Buy' from analysts, with 1 recommending a buy and none suggesting a sell or hold.

Wewin's stock (WEWIN) has a volatility of 13.74% and a beta coefficient of 0.47.